Alkermes Plc (ALKS) SVP Laurie Keating Sells 6,249 Shares

Alkermes Plc (NASDAQ:ALKS) SVP Laurie Keating sold 6,249 shares of Alkermes stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of Alkermes Plc (NASDAQ:ALKS) traded up $0.32 during midday trading on Thursday, reaching $52.12. The company’s stock had a trading volume of 640,200 shares, compared to its average volume of 852,385. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes Plc has a 1 year low of $46.42 and a 1 year high of $63.40.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The firm had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. equities research analysts anticipate that Alkermes Plc will post -0.59 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of ALKS. Janus Henderson Group PLC grew its stake in Alkermes by 13,784.0% in the second quarter. Janus Henderson Group PLC now owns 2,330,992 shares of the company’s stock valued at $135,128,000 after purchasing an additional 2,314,203 shares in the last quarter. Thornburg Investment Management Inc. lifted its position in shares of Alkermes by 39.8% in the third quarter. Thornburg Investment Management Inc. now owns 2,779,364 shares of the company’s stock worth $141,303,000 after buying an additional 790,692 shares during the last quarter. Fiera Capital Corp acquired a new stake in shares of Alkermes in the second quarter worth about $37,717,000. Vanguard Group Inc. lifted its position in shares of Alkermes by 3.7% in the second quarter. Vanguard Group Inc. now owns 12,546,198 shares of the company’s stock worth $727,303,000 after buying an additional 449,563 shares during the last quarter. Finally, Asset Management One Co. Ltd. lifted its position in shares of Alkermes by 6,353.1% in the third quarter. Asset Management One Co. Ltd. now owns 234,377 shares of the company’s stock worth $11,924,000 after buying an additional 230,745 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

ALKS has been the topic of a number of research analyst reports. ValuEngine upgraded Alkermes from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Jefferies Group set a $69.00 price target on Alkermes and gave the company a “buy” rating in a report on Friday, August 25th. Citigroup set a $62.00 price target on Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. Credit Suisse Group lowered their price target on Alkermes from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. Finally, Barclays set a $50.00 price target on Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $63.55.

COPYRIGHT VIOLATION WARNING: “Alkermes Plc (ALKS) SVP Laurie Keating Sells 6,249 Shares” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/21/alkermes-plc-alks-svp-laurie-keating-sells-6249-shares.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit